Form D · Biotechnology
Acylin Therapeutics, Inc.
Seattle, WA · CIK 0001506358
Offering snapshot reported Jun 4, 2012 · SEC filing
- Reported sold
- $2M Offering amount: $2M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 23, 2012 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 4, 2012 | Initial | $2,000,000 | No comparison | 5 | SEC filing |
| Dec 1, 2010 | Initial | $320 | No comparison | 2 | SEC filing |
| Dec 1, 2010 | Initial | $2,000,000 | No comparison | 7 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-179179
Series A-1 Convertible Preferred Stock
Source: Form D, filed Jun 4, 2012. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lee Babiss | Director |
| Peter Di Stefano | Director |
| Steven Gillis | Director |
| Steven Gills | Director |
| Thong Le | Director |
| Janis Naeve | Director |
| Lindsay Rayle | Executive |
| Chad Waite | Director |
| Carl Weissman | Director, Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
1616 Eastlake Ave, Suite 203
Seattle, WA, 98102
Seattle, WA, 98102